Medicus Pharma CEO Raza Bokhari says the company has filed a registration study with the FDA for SkinJect in Gorlin syndrome, aiming for an open-label trial of about 50 patients with visual clearance as the endpoint. He frames this as a potentially faster path to a new drug application, supported by orphan-drug and pediatric rare-disease designation efforts, while also stressing a new $22 million institutional investment that lifted cash to roughly $30 million and extended runway beyond 24 months.
Watch on YouTube ›Get the market thesis, key claims, assets, contradictions, and follow-up questions from any financial video — then unlock a version personalized to your portfolio, watchlist, and favorite speakers.
This interview centers on Medicus Pharma’s latest regulatory and financing milestones around SkinJect, its lead non-invasive treatment platform for non-melanoma skin disease, especially basal cell carcinoma and Gorlin syndrome. CEO Raza Bokhari says the company has moved from early development into a more advanced phase, citing a clean, decision-grade phase 2 dataset and “accelerating our partnering discussions” as evidence that the program is gaining momentum. The main thesis is that Gorlin syndrome may represent a special regulatory and commercial path for SkinJect. Bokhari says Medicus has filed a registration study with the FDA for Gorlin patients using a visual clearance endpoint, and he believes an open-label study of roughly 50 patients could be enough to support a future NDA. …
Tactically, the setup is driven by FDA feedback and any near-term follow-up on the Gorlin study; the fresh cash position lowers dilution pressure, but the stock remains event-sensitive.
Over the next few months, the story should trend positively only if the FDA accepts the registrational framework and the study executes cleanly; otherwise the market may treat it as another early-stage biotech wait-and-see.
The durable thesis is that rare-disease biotech value can be created through regulatory positioning, orphan benefits, and focused indication strategy, but that only matters if the platform repeatedly clears FDA and clinical hurdles.
Medicus has filed a registration study with the FDA for Gorlin syndrome patients using a visual-clearance endpoint.
This is the central regulatory update and the basis for the interview.
A promising dataset could support a new drug application and commercial availability for Gorlin syndrome patients.
He links the study path to eventual NDA and commercialization.
The company believes about 50 open-label patients may be enough for the Gorlin registration study.
This is a concrete trial-size assertion that matters to the path forward.
You've had another significant milestone when it comes to the regulatory world and SkinJect and dealing with Gorlin syndrome. So maybe you can kind of take us back here and explain how SkinJect can help.
Bokhari explains that SkinJect is Medicus Pharma’s lead non-invasive therapy for non-melanoma skin disease, especially basal cell carcinoma, and that the company is moving it into a registrational study for Gorlin syndrome.
There are many benefits that you can get going forward from that. Correct?
He says orphan-drug designation could provide seven years of exclusivity, a filing-fee waiver, and potentially a pediatric rare disease voucher, though the key condition is still successful regulatory progression.
I want to shift also to to some financing that you were able to get completed.
He says an institutional investor invested a little over $22 million, bringing cash to about $30 million and giving more than 24 months of runway, which he says reduces dilution anxiety.
Unlock the full claims, asset map, scores, related transcripts, follow-up questions, and AI chat — shaped around your portfolio, watchlist, favorite speakers, and risks.
